Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06596044 · ClinicalTrials.gov registry record · NA

Suicide Prevention After Community Care Discharge

A NA study of Suicide Prevention, sponsored by VA Office of Research and Development.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT06596044: Recruiting NA study of Suicide Prevention, sponsored by VA Office of Research and Development.

NCT06596044 is a NA study of Suicide Prevention that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 120 participants, below the 947-participant average among 21 other Suicide Prevention trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06596044, a NA study of Suicide Prevention, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The study is of high importance to Veterans' health because it will study a suicide prevention intervention in a Veteran population that is at high risk of suicide but has not been a specific focus of the Veteran Affairs' (VA's) suicide prevention efforts. Specifically, a growing number of Veterans are now receiving acute mental health treatment in VA-purchased settings (commonly referred to as Community Care). While these Veterans are at high risk of suicide after discharge, very little is known about how to prevent suicide in these Veterans. This study will directly address this problem by looking at whether a promising suicide prevention strategy called the VA Brief Intervention and Contact Program (VA BIC) can decrease the risk of suicide in Veterans after they are discharged from a non-VA mental health treatment setting. The proposed research is highly pertinent to the VA's top clinical priority-to prevent suicide in Veterans.

Primary Outcome

The Beck Scale for Suicidal Ideation (BSS) is a self-reported, 21-item scale that assesses symptoms of suicidal ideation. The total score ranges from 0-38. While there is no established BSS cutoff score to classify suicide risk, there is evidence that higher scores on the BSS correspond to more severe suicidal ideation and that a change of five points or more on the total BSS scores may be clinically relevant.

Conditions Studied

Interventions

  • OTHER Standard Care
  • BEHAVIORAL VA BIC

Study Locations (1)

Vermont

  • White River Junction VA Medical Center, White River Junction, VT - White River Junction

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-10-01
Est. Completion 2028-09-30
Phase NA
VA Office of Research and Development

1,668 total trials

What NCT06596044 shows while recruiting

NCT06596044 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 947-participant average among 21 other Suicide Prevention trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Suicide Prevention appearing as the primary indexed condition, and to 2 interventions - of which Standard Care is the first listed.

NCT06596044 reports a single indexed study location in Vermont.

Frequently Asked Questions

What is clinical trial NCT06596044 about?

NCT06596044 is a clinical study titled "Suicide Prevention After Community Care Discharge". The study is of high importance to Veterans' health because it will study a suicide prevention intervention in a Veteran population that is at high risk of suicide but has not been a specific focus of the Veteran Affairs' (VA's) suicide prevention efforts. Specifically, a growing number of Veterans ...

What is the current status of trial NCT06596044?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-10-01. Estimated completion is 2028-09-30.

What conditions does trial NCT06596044 study?

This clinical trial studies the following conditions: Suicide Prevention.

What interventions are being tested in trial NCT06596044?

The interventions under investigation include: Standard Care (OTHER), VA BIC (BEHAVIORAL).

Who is sponsoring clinical trial NCT06596044?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06596044 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Suicide Prevention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06596044's enrollment target sits among peer trials

120 15th of 21 higher than 6 of 21 other Suicide Prevention trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Suicide Prevention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06596044, the US trial registry maintained by the National Library of Medicine. NCT06596044 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.